Results 11 to 20 of about 9,741 (153)

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]

Br J Clin Pharmacol
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Dello Russo C, Frater I, Kuruvilla R, Lip S, O'Neill H, Burke K, Chaplin V, Doney ASF, Elyas S, Greaves N, Harding S, Hargroves D, Hayward J, Hughes DA, Hughes TAT, Kondapally S, Mok P, Peace A, Rafi I, Ray S, Stinton V, Venetucci L, Pirmohamed M.   +22 more
europepmc   +2 more sources

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

Thrombosis Journal, 2018
Background Although prasugrel exerts stronger antiplatelet effects compared with clopidogrel, the factors affecting platelet reactivity under prasugrel have not been fully determined. This study aimed to find the novel mechanistic differences between two
Satoshi Niijima, Tsukasa Ohmori, Kazuomi Kario   +2 more
doaj   +1 more source

Platelet Blockage: Prasugrel versus Ticagrelor: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5

Journal of the Practice of Cardiovascular Sciences, 2019
The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 trial randomized patients with acute coronary syndrome for whom invasive treatment was planned to ticagrelor versus prasugrel.
Venkatakrishnan Ramakumar
doaj   +1 more source

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions

Indian Heart Journal, 2018
Background: Although conventional 60 mg of prasugrel allows for rapid and potent platelet inhibition within 30 min after loading dose, the efficacy and safety of lower doses of prasugrel in Indian patients has not yet been investigated.
Priti Kumari, Bhanwar Lal Ranwa
doaj   +1 more source

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms [PDF]

Neurointervention, 2018
Thromboembolism is one of the major complications of stent assisted coiling in treatment of cerebral aneurysm. Clopidogrel resistance is so common and prasugrel is more effective in its rapid and potent effect.
Dongwhane Lee, Yunsun Song, Minkyu Han, Danbi Park, Dae Chul Suh   +4 more
doaj   +1 more source

WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

Рациональная фармакотерапия в кардиологии, 2018
The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS).
M. Yu. Gilyarov, Е. V. Konstantinova
doaj   +1 more source

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundEarly withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST‐segment elevation myocardial infarction (
Konstantinos C. Koskinas, Thomas Zanchin, Roland Klingenberg, Baris Gencer, Fabrice Temperli, Andreas Baumbach, Marco Roffi, Aris Moschovitis, Oliver Muller, David Tüller, Stefan Stortecky, Francois Mach, Thomas F. Lüscher, Christian M. Matter, Thomas Pilgrim, Dik Heg, Stephan Windecker, Lorenz Räber   +17 more
doaj   +1 more source

Simultaneous Determination of Prasugrel and Aspirin by Second Order and Ratio First Order Derivative Ultraviolet Spectrophotometry

Journal of Spectroscopy, 2013
Two simple, accurate, and precise UV derivative spectrophotometric methods for the simultaneous determination of Prasugrel and Aspirin in synthetic mixture form have been developed. The first method involves measurement of second order derivative spectra
Shahabuddin N. Alvi, Mehul N. Patel, Prakash B. Kathiriya, Bhavna A. Patel, Shraddha J. Parmar   +4 more
doaj   +1 more source

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2020
Background This meta-analysis aimed to compare the effects of prasugrel and ticagrelor on high (HTPR) and low on-treatment platelet reactivity (LTPR) in patients with acute coronary syndrome (ACS).
Mingxiang Wen, Yaqi Li, Xiang Qu, Yanyan Zhu, Lingfang Tian, Zhongqin Shen, Xiulin Yang, Xianqing Shi   +7 more
doaj   +1 more source